Application of Low Intensity Ultrasound in the Treatment of Alzheimer’s Disease
Alzheimer’s disease (AD) is a common neurodegenerative disease in clinical practice. The pathogenesis is still unclear, and there is no specific method. According to the current known pathological studies, AD biomarker TAU protein, phosphorylated tau and amyloid-β (Aβ) play an important role in the...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of Advanced Ultrasound in Diagnosis and Therapy
2025-03-01
|
| Series: | Advanced Ultrasound in Diagnosis and Therapy |
| Subjects: | |
| Online Access: | https://www.journaladvancedultrasound.com/fileup/2576-2516/PDF/1738998944954-44645644.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Alzheimer’s disease (AD) is a common neurodegenerative disease in clinical practice. The pathogenesis is still unclear, and there is no specific method. According to the current known pathological studies, AD biomarker TAU protein, phosphorylated tau and amyloid-β (Aβ) play an important role in the pathophysiological changes of AD. For pathological research, the development of low-intensity ultrasound (LIUS) provides another idea for the mechanism of AD treatment, which can better treat AD, regulate various factors specifically, and effectively treat AD by stimulating synapses and improving neurons. Based on this research background, this paper summarizes the role of AD biomarkers TAU protein, phosphorylated tau and amyloid protein in the occurrence and development of AD and the mechanism of pathological changes in the treatment of AD by low-intensity ultrasound, aiming to provide new insights into clarifying the pathological changes of AD biomarkers and the mechanism of LIUS in the treatment of AD. Given that the treatment for AD based on LIUS is still far from a complete cure, we will discuss the prospects for future development of LIUS to guide the treatment of AD. |
|---|---|
| ISSN: | 2576-2516 |